BTIG initiated coverage on Rani Therapeutics Hldgs with a new price target
$RANI
Biotechnology: Pharmaceutical Preparations
Health Care
BTIG initiated coverage of Rani Therapeutics Hldgs with a rating of Buy and set a new price target of $24.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/2/2024 | $17.00 | Outperform | Oppenheimer |
| 6/14/2024 | $15.00 | Buy | Maxim Group |
| 6/13/2024 | $10.00 | Buy | Rodman & Renshaw |
| 4/17/2023 | $24.00 | Buy | BTIG Research |
| 10/11/2022 | $15.00 | Buy | UBS |
| 7/27/2022 | $22.00 | Buy | H.C. Wainwright |
| 6/13/2022 | $28.00 | Outperform | Wedbush |
| 8/25/2021 | $24.00 | Buy | BTIG |
- Research agreement is evaluating feasibility of applying Rani's oral delivery technology to Chugai's antibodies against undisclosed targets - SAN JOSE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the company has entered into a Research Agreement on 13th August, 2024, for two molecules with undisclosed targets provided by Chugai Pharmaceutical Co., Ltd. ("Chugai"). The full analysis confirms the RaniPill® delivery demonstrated comparable bioavailability to the subcutaneous route of delivery for both mol
- Announced preclinical data demonstrating the bioequivalence of RT-114, a bispecific GLP-1/GLP-2 receptor agonist (PG-102), delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 - - Phase 1 study for RT-114 for the treatment of obesity expected to initiate in mid-2025 - - Announced preclinical data demonstrating successful oral delivery of semaglutide via RaniPill® capsule - SAN JOSE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the first quarter ende
- Announced preclinical data demonstrating the bioequivalence of RT-114, a GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 - - Announced preclinical data demonstrating successful oral delivery of semaglutide via RaniPill® capsule - - Preclinical data of four incretin-based molecules underscores the RaniPill® platform's potential to facilitate the oral delivery of a diverse array of obesity treatments - - Phase 1 study for RT-114 for the treatment of obesity, expected to initiate in mid-2025 - - Conference call today at 4:30 p.m. ET / 1:30 p.m. PT - SAN JOSE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Rani Therapeut
4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
Oppenheimer initiated coverage of Rani Therapeutics with a rating of Outperform and set a new price target of $17.00
Maxim Group initiated coverage of Rani Therapeutics with a rating of Buy and set a new price target of $15.00
Rodman & Renshaw initiated coverage of Rani Therapeutics with a rating of Buy and set a new price target of $10.00
- Expansion of partnership with Celltrion for development of RT-105 to complement existing partnership for RT-111 - Appointment of Kate McKinley as Chief Business Officer - Presentation of three abstracts on RT-102 and RT-112 at the Endocrine Society Annual Conference and selection as winner of Presidential Poster Competition in its category for exceptional scientific work on RT-102 - Presentation of late-breaking abstract on oral delivery of GLP-1 agonist at American Diabetes Association's Scientific Sessions - Plan to initiate Phase 2 study for RT-102 and Phase 1 study for RT-111 in 2H of 2023 SAN JOSE, Calif., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings,
SAN JOSE, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has appointed Kate McKinley as its Chief Business Officer. "Kate is a seasoned industry leader, and we are thrilled to welcome her to Rani's executive team," said Talat Imran, Chief Executive Officer of Rani. "Kate's expertise in corporate strategy, business development and commercialization will further strengthen our leadership team and partnering efforts, while positioning the Company for its next stage of growth. Kate will have a vital role
- Initiated a Phase 1 clinical trial of RT-102 for the treatment of osteoporosis – - Unveiled the high-capacity RaniPill™ HC, capable of delivering payloads of up to 20 mg – - Strengthened Board with the appointment of Lisa Rometty - SAN JOSE, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update. "We started the year off strong, having unveiled the high-capacity RaniPill HC, advanced RT-102 into the clinic for a Phase 1 trial in o
SC 13G - Rani Therapeutics Holdings, Inc. (0001856725) (Subject)
SC 13D/A - Rani Therapeutics Holdings, Inc. (0001856725) (Subject)
SC 13D/A - Rani Therapeutics Holdings, Inc. (0001856725) (Subject)
4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
8-K - Rani Therapeutics Holdings, Inc. (0001856725) (Filer)
424B5 - Rani Therapeutics Holdings, Inc. (0001856725) (Filer)
10-Q - Rani Therapeutics Holdings, Inc. (0001856725) (Filer)
- Announced preclinical data demonstrating the bioequivalence of RT-114, a GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 - - Announced preclinical data demonstrating successful oral delivery of semaglutide via RaniPill® capsule - - Preclinical data of four incretin-based molecules underscores the RaniPill® platform's potential to facilitate the oral delivery of a diverse array of obesity treatments - - Phase 1 study for RT-114 for the treatment of obesity, expected to initiate in mid-2025 - - Conference call today at 4:30 p.m. ET / 1:30 p.m. PT - SAN JOSE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Rani Therapeut
SAN JOSE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2024 and provide a business update on Monday, March 31, 2025 after the close of trading. Rani's management team will host a conference call and webcast beginning at 4:30 p.m. ET. Conference Call and Webcast Rani Therapeutics will host a conference call and live webcast at 4:30 p.m. ET / 1:30 p.m. PT on March 31, 2025. Individuals interested in listenin
~ New RT-114 obesity program combines ProGen's FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with the RaniPill® capsule designed to provide a differentiated oral delivery mechanism with bioavailability comparable to subcutaneous injection ~ ~ Rani and ProGen to share responsibilities for the development and commercialization of RT-114, including a 50/50 cost and revenue share arrangement ~ ~ Rani to host conference call today at 8:00 a.m. ET/5:00 a.m. PT ~ SAN JOSE, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani")(NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and